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Variations in OPRK1, which encodes the k-opioid receptor, are associated with the risk for alcohol depen-
dence. Sequencing DNAs with higher and lower risk haplotypes revealed an insertion/deletion (indel) with
a net addition of 830 bp located 1986 bp upstream of the translation start site (1389 bp upstream of the tran-
scription start site). We demonstrated that the upstream region extending from 21647 to 210 bp or from
22312 to 210 bp (relative to the translation start site) could function as a promoter in transient transfection
assays. We then determined that the presence of the indel reduced transcriptional activity by half. We used a
PCR assay to genotype individuals in 219 multiplex alcohol-dependent families of European American des-
cent for the presence or absence of this indel. Family-based association analyses detected signiﬁcant evi-
dence of association of this insertion with alcoholism; the longer allele (with the indel), which had lower
expression, is associated with higher risk for alcoholism. This indel is, therefore, a functional regulatory vari-
ation likely to explain at least part of the association of OPRK1 with alcohol dependence.
INTRODUCTION
Opioids regulate many brain functions relevant to addictions,
including reward, reinforcement, mood and psychomotor
stimulation (1–5). In particular, stimulation of the k-opioid
receptor (KOR) reduces the release of dopamine in the
nucleus accumbens of the mouse and generates aversive
states (1,2). The effects of stimulating or inhibiting the
k-opioid system are complex and may be affected by
species, strain, duration of exposure and drinking paradigm
(6). Stimulating the KOR with a selective KOR agonist
reduces voluntary ethanol intake in rats in a two-bottle
choice paradigm (7), but chronic treatment potentiated
ethanol intake during the alcohol deprivation effect in rats
that had long-term exposure to ethanol (3). Blocking the
KOR in mice that normally drink ethanol (C57/BL6) with a
KOR-speciﬁc antagonist, nor-binaltorphimine, increases
alcohol self-administration (8). Walker and Koob (9) reported
that nor-binaltorphimine selectively reduced ethanol self-
administration in rats made dependent on ethanol but not in
non-dependent rats. Mice in which the KOR has been dis-
rupted drink half as much ethanol as either wild-type or het-
erozygous mice (10). Ethanol treatment, particularly in
combination with cocaine, reduces KOR mRNA in the VTA
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the nucleus accumbens to a greater extent in KOR
2/2 mice
than in wild-type mice, and nor-binaltorphimine increased
ethanol-evoked dopamine levels (12). Chronic ethanol
treatment led to increased dynorphin B in the nucleus accum-
bens which persisted at least 21 days after ceasing treatment
(13). The k-opioid system also appears to be involved in
ethanol withdrawal-related seizures (14–16).
A recent family-based study in European Americans
demonstrated that variations in OPRK1, the gene encoding
the KOR, and in PDYN, which encodes its dynorphin ligand,
were associated with alcohol dependence (17). The associated
SNPs in OPRK1 were in intron 2 of the gene; two coding
SNPs were not associated (17). The association of OPRK1
with alcoholism was conﬁrmed by a second study, reporting
that a haplotype of OPRK1 was associated with alcohol depen-
dence (18), although individual SNPs were not; it should be
noted that Zhang et al. (18) did not test any SNPs in intron
2, the region where association had earlier been reported. An
earlier study of three coding SNPs in Taiwanese Han subjects
found no association between OPRK1 and alcohol dependence
(19). The ﬁnding that non-coding SNPs, but not coding SNPs,
were associated with alcohol dependence suggests that the
association is with regulatory variation in the gene. Non-
coding OPRK1 variations have also been associated with
opioid addiction (20), as was the coding SNP G36T (21).
The association of variants in PDYN with alcohol dependence
was also replicated (22). Variations in other opioid receptor
genes were not associated with alcohol dependence in the
same large, family-based sample in which the association
with OPRK1 was reported (17). The involvement of genes
encoding both an opioid receptor (OPRK1) and its ligand
(PDYN) makes biological sense, indicating that variations in
signaling through this system, by varying either the ligand
or receptor, affect alcohol consumption and alcohol depen-
dence.
OPRK1 is located on human chromosome 8q11.2. There are
four exons within the 22 kb gene (RefSeq NM_000912); the 50
exon is non-coding (21,23). When we found that non-coding
variations in OPRK1 were associated with alcohol dependence
(17), we sequenced DNA from individuals with different hap-
lotypes to identify additional variations. We identiﬁed a pre-
viously unknown insertion/deletion (indel) and examined its
effect on the regulation of gene expression. We also tested
whether that indel was associated with alcoholism.
RESULTS
Polymorphisms in the OPRK1 promoter region
Sequencing the exons and proximal 50 region of OPRK1 in 16
human samples (half carrying the lower risk and half carrying
the higher risk haplotype) led to the detection of six new SNPs
(reported to dbSNP: rs35970029, rs34418807, rs35991105,
rs34709943, rs35373196, rs35160174). At all of the SNPs,
the lower risk samples were homozygous for the reference
sequence, whereas some of the higher risk samples were
heterozygous. We also detected a new complex indel
involving the deletion of 11 bp from 21975 to 21985 (all
positions are relative to the reference genome sequence
NT_008183.18 and the translation start site of OPRK1,
RefSeq NM_000912) and the insertion of 841 bp at
21986 bp relative to the reference genome sequence, for a
net insertion of 830 bp (reported to dbSNP: rs35566036).
All eight of the samples with the lower risk haplotype
lacked the indel and matched the reference genome sequence.
All the eight of the samples with the higher risk haplotype had
a copy of the indel. A diagram of the gene, based upon
the reference sequence, is shown in Figure 1. The minor
allele containing the indel is ancestral; BLAST analysis
shows that the indel is contained in the Chimp genome
(NW_001240342.1) and in the genome of the Rhesus
macaque (AC202275.5).
Effects of indel on gene expression
To determine whether the presence of the indel affected tran-
scription in vitro, transient transfection assays were carried
out. First, the promoter region extending approximately
Figure 1. 50 region of the OPRK1 gene and fragments used in promoter assays.
Boxes 1 and 2 are exons; gray, 50 untranslated sequence; black, coding
sequence. Transcription in direction of top arrow. 1.6 kb is the fragment
extending from 21647 to 210 bp relative to the translation start site;
2.3 kb is the fragment with the reference sequence, from 22312 to 210 bp;
3.1 kb is the fragment with the same ends but containing the additional
830 bp of the indel (minor allele).
Figure 2. Effect of the indel on promoter function in vitro. Black bars represent
the mean expression, gray bars are +1 standard error. 1.6 kb is the fragment
extending from 21647 to 210 bp relative to the translation start site; 2.3 kb is
the fragment with the reference sequence, from 22312 to 210 bp; 3.1 kb is
the fragment from 22312 to 210 bp but containing the additional 830 bp indel.
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with that extending to 22.3 kb on the reference sequence, in
DNA without the indel (Fig. 2). The additional 665 bp had a
small but signiﬁcant negative effect upon gene expression,
reducing it to 87% that of the shorter fragment (P , 0.01).
Next, the construct with the indel (3.1) was compared with
its counterpart without the indel (2.3). The presence of the
indel lowered transcription activity to 53% of that in its
absence (P , 10
211).
Association of the indel with alcohol dependence
The strong effect of the indel on gene expression, and the
ﬁnding that it was common to eight individuals with the
higher risk haplotype of OPRK1, led us to examine its poten-
tial association with alcoholism. We genotyped 1914 individ-
uals in 219 European American families in which at least three
ﬁrst-degree relatives were alcohol dependent. Genotyping was
by PCR ampliﬁcation followed by size determination of the
fragments on agarose gels (Fig. 3). The reference sequence
was the major allele. The allele with the indel (the net
830 bp insertion) was the minor allele, with a frequency of
28% in these families; genotypes were in Hardy–Weinberg
equilibrium. The indel was in high LD (as measured by D0)
with all of the SNPs we had previously genotyped (17) (data
not shown). However, owing to differences in allele frequen-
cies, the indel had only a low correlation (r
2) with many of
the SNPs (Fig. 4).
Family-based association analysis by the Pedigree Disequi-
librium Test (PDT) demonstrated that the indel was associated
with alcohol dependence (P ¼ 0.01). The minor allele, with
the net additional 830 bp, was overtransmitted to affected indi-
viduals (265 transmissions versus 235 non-transmissions) and
overtransmitted to the affected sibling in a discordant sibling
pair (495 transmissions to the affected sibling; 453 trans-
missions to the unaffected sibling). Reanalyzing the data
after coding as ‘unknown’ individuals who were not alcohol
dependent but were dependent on other illicit drugs (in case
there was shared genetic vulnerability at this locus) yielded
a similar result (P ¼ 0.02). Comparing the pattern of associ-
ation results previously reported for SNPs (17) with that of
LD as measured by r
2 (Fig. 4), we found that four of the
ﬁve SNPs for which r
2 with the indel was .35% were signiﬁ-
cant and the ﬁfth was marginal; in contrast, only one of the
eight SNPs for which r
2 with the indel was lower (,35%)
was signiﬁcant and one was marginal.
DISCUSSION
We previously reported that SNPs in intron 2 of OPRK1, the
gene encoding the KOR, were associated with alcohol depen-
dence; three synonymous SNPs were not associated (17). To
better understand this association, we sequenced DNA from
individuals with higher risk and lower risk alleles to detect
additional genetic variations. Sequencing revealed several
novel SNPs along with an indel upstream of the translation
start site. This indel, at 21986, added a net 830 bp of
sequence and was present in the sequenced individuals who
were alcohol dependent. The indel was in high LD with
most of the SNPs that we had previously reported associated
with alcohol dependence (17). Here we demonstrate that the
50 region of OPRK1 can function as a promoter in vitro.W e
then analyzed the effect of the indel on gene expression. Pre-
sence of this indel reduced transcription by nearly half. Geno-
typing and family-based analysis of our data set of multiplex
alcohol-dependent families demonstrated that this indel was
signiﬁcantly associated with alcoholism. Therefore, we con-
clude that this indel is a functional variation that explains at
least part of the association of OPRK1 with alcoholism.
The k-opioid system has been implicated in several effects
of ethanol. The effects on ethanol consumption of modulating
the k-opioid system are complex and differ in different
species, strains and conditions (6). Stimulation of the KOR
reduces voluntary ethanol drinking in rats (7). Blocking the
KOR increases voluntary ethanol intake in C57/BL6 mice
(8). Although the phenotype of voluntary drinking of ethanol
is clearly not the same as alcohol dependence, these results
are consistent with our results, which demonstrate that the pre-
sence of the indel that reduced gene expression in vitro by half
was associated with a higher risk for alcoholism. In a different
system, a selective KOR antagonist reduced ethanol self-
administration in rats that had been made dependent on
ethanol, but not on control rats (9). Mice homozygous for a
disruption in Oprk1 drink less ethanol in a two-bottle choice
paradigm than either wild-type or heterozygous mice (10),
however, suggesting that complete deletion of the KOR
reduces drinking in mice, but a 50% reduction in KOR
levels may not affect it. Again, alcohol dependence in
humans is a much more complex phenotype.
Our study demonstrates that an indel 1986 bp upstream of
the translational start site in OPRK1 reduces promoter activity
by about half and is associated with alcohol dependence.
These data represent the demonstration of a functional
variant in OPRK1 that is associated with alcoholism.
MATERIALS AND METHODS
Subjects
Subjects were members of families in which at least three
ﬁrst-degree relatives were alcohol dependent [meeting both
Figure 3. Genotyping of the indel. PCR was carried out with primers HE3236
and HE3244 as described in the text, followed by electrophoresis on 1%
agarose gels. A homozygote lacking the indel is shown as SS, a homozygote
with the indel as LL and a heterozygote as SL. M is a 100 bp DNA ladder
(New England Biolabs, Ipswitch, MA, USA); the darker bands are 500 and
1000 bp.
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and Feighner criteria for deﬁnite alcohol dependence (25)].
Only non-Hispanic families of European American descent
(219 families) were analyzed. The ascertainment and assess-
ment have previously been described (26,27) and are available
in detail at zork.wustl.edu/niaaa/coga_instruments/resources.
html. A genetically informative subset of families was selected
as described in more detail by Foroud et al. (27). Subjects
were collected at six centers in the USA: Indiana University,
State University of New York Health Science Center, Univer-
sity of Connecticut, University of Iowa, University of Califor-
nia/San Diego and Washington University, St Louis. The
institutional review boards of all participating institutions
approved the study. Probands were identiﬁed through alcohol-
ism treatment programs, and after providing written informed
consent, probands and their relatives were administered a vali-
dated poly-diagnostic instrument, the Semi-Structured Assess-
ment for the Genetics of Alcoholism (SSAGA) interview
(28,29).
DNA sequencing
The OPRK1 50 region and ﬁrst exon, from 22312 (numbering
here is relative to the translational start site ATG in RefSeq
NM_000912) to þ453, were ampliﬁed from 16 human
genomic DNAs, eight from individuals with the higher risk
haplotype and eight with the lower risk haplotype previously
described (17). Primers (Table 1) were designed on the basis
of the NCBI reference genome contig (NT_008183.18). We
used the primer pairs shown in Table 2 to amplify the
region from 22312 to þ452 in four overlapping fragments.
PCR products were directly sequenced using the ABI
BigDye Terminator Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA) and separated on an ABI 3100
Genetic Analyzer (Applied Biosystems). Sequences were
aligned using MacVector (MacVector Inc., Cary, NC, USA),
and polymorphic sites were checked on the electropherograms.
New sequences were submitted to dbSNP (SNPs: rs35970029,
rs34418807, rs35991105, rs34709943, rs35373196, rs35160174;
indel rs35566036).
Cloning of OPRK1 upstream regions
Two human genomic DNAs were chosen as templates to
amplify the OPRK1 upstream regions, one containing the
Figure 4. Linkage disequilibrium among genotyped markers (r
2). At top is a diagram of the gene showing the relative position of the oprk1ins indel (rs35566036)
and of the SNPs previously reported (17); associated SNPs are boxed. Below is a diagram of LD between SNPs, calculated as r
2.















1786 Human Molecular Genetics, 2008, Vol. 17, No. 12indel (6006) and one lacking it (5003). The primer pairs are
listed in Table 3; we added a SalI site at the 50 end and a
KpnI site at the 30 end of the fragments to facilitate cloning
into the luciferase reporter plasmid pXP2 (30). Ampliﬁed
fragments were puriﬁed, digested with SalI and KpnI and
cloned into pXP2 that was similarly digested. Identity of the
fragments was conﬁrmed by restriction mapping and DNA
sequencing.
Transient transfection assays
HepG2 cells were grown in six-well plates (Corning, NY,
USA) in MEM with 10% fetal bovine serum (FBS; Life Tech-
nologies, Rockville, MD, USA) and 2 mM glutamine. Cells
(3.6   10
5 cells per well) were washed with 2 ml of medium
without FBS and then transfected using Fugene 6 (Roche
Diagnostics, Indianapolis, IN, USA) with a total of 3.3 mg
DNA (2 mg test plasmid, 0.13 mg pCMV-b-galactosidase as
an internal control and 1.2 mg pUC19 DNA) for 5 h. Complete
medium (2 ml) containing FBS was then added and incubation
was continued for 25 h. Cells were washed with 1 
phosphate-buffered saline and resuspended in 100 mlo f1  
reporter lysis buffer (Promega, Madison, WI, USA). Cells
were lysed by three freeze–thaw cycles, followed by vortex
mixing for 15 s. Twenty microliters of each lysate was
assayed for luciferase activity using the Luciferase Assay
System (Promega), with activity measured for 60 s on an
Lmax Plate Luminometer (Molecular Devices, Sunnyvale,
CA, USA). Five microliters of each lysate was assayed for
b-galactosidase activity for 30 s using the Galacto-Light
TM
Plus System (Applied Biosystems, Benford, MA, USA) and
the Lmax Plate Luminometer.
In each of four independent experiments, the test constructs
and external positive control (pXP2 with an unrelated promo-
ter for normalization) and negative control (pXP2 without
a promoter fragment) were transfected in triplicate.
Luciferase activity/b-galactosidase activity was calculated
for each sample and then normalized to the average of the
three external controls in the same experiment, with the
average value of the external controls set to 100. Data are pre-
sented as mean relative luciferase activity +1 standard error
of the mean. Signiﬁcance was determined by a t-test (two-
tailed, unequal variance; Microsoft Excel). Negative controls
averaged 0.8% of the positive control.
Genotyping
Allele frequencies for the indel were determined by PCR
ampliﬁcation of 30 ng of genomic DNA using HE3026/
HE3027 (Table 1; Fig. 1); this yields a 736 bp fragment in
the reference genomic sequence (NT_008183.18) or a
1566 bp fragment if the indel is present. HotStar Taq
(Qiagen, Valencia, CA, USA) was used to minimize back-
ground. The ﬁnal reaction contained 1  PCR buffer,
200 mM of each dNTP, 3.5 mM Mg
2þ,1   Q-solution,
0.4 mM primer, 1.5 unit of HotStarTaq DNA polymerase
(Qiagen) in 15 ml total volume. PCR reactions were carried
out in GeneAmp PCR system 9700 (Applied Biosystems,
CA, USA) using the following conditions: 958C 15 min to
activate the HotStarTaq polymerase, then 35 cycles of 958C
for 20 s, 608C for 15 s, 728C for 2 min 45 s, ﬁnal extension
at 728C for 10 min. Aliquots of the PCR products (6 ml)
were separated on 1% agarose gels (E-Gel 96, Invitrogen,
CA, USA). Each gel was read independently by two people,
and the data were combined by a third individual.
There were dropouts from the initial genotyping, so fresh ali-
quots of DNA from those individuals were analyzed using a
different primer pair, HE3236/HE3244 (Table 1), which
yielded a 336 bp band (without indel) or a 1166 bp band with
the indel; we reasoned that reducing the size of the fragments
should make the assay more robust to potential DNA degra-
dation. The ﬁnal reaction contained 1  R-Taq Master Mix
(Bulleye R-Taq DNA pol 2.0  Mix, MidWest Scientiﬁc, St
Louis, MO, USA), 0.375 mM primer in 20 ml total volume
with 15 ng genomic DNA. PCR reactions were carried out in
GeneAmp PCR system 9700 (Applied Biosystems) using the
following conditions: 958C for 3 min for initial DNA denatura-
tion, then 35 cycles of 948C for 20 s, 628C for 15 s, 728C for
1 min 30 s, ﬁnal extension at 728C for 7 min. Aliquots (6 ml)
of PCR product were separated on 2% agarose gels (E-Gel 96,
Invitrogen) and independently read by three individuals. Only
unambiguous data were used. Results of the genotyping were
tested for Mendelian inheritance using the program PED-
CHECK (75). Marker allele frequency and heterozygosity
were computed using the program USERM13 (76).
Statistical analyses
Family-based association analyses were performed using PDT
(78) as implemented in the program UNPHASED (version
2.404) (31). Individuals were considered affected if they
were alcohol dependent on the basis of meeting both




HE3026/HE3027 22312 to 21577 736 (no indel); 1566 (with indel)
HE3028/HE3029 21647 to 2928 720
HE3040/HE3041 21118 to 2381 738
HE3032/HE3033 2428 to 453 881
aPosition relative to the translational start site of OPRK1 (NM_000912) on
the NCBI reference genome (NT_008183.18).
Table 3. OPRK1 constructs for transfection assays
Name Position
a Primer pairs DNA
b Length (bp)
OPRK-1.6 21647 to 210 HE3059/HE3061 5003 1638
OPRK-2.3 22312 to –10 HE3058/HE3061 5003 2303




Fragments noted were cloned into pXP2 for assays of promoter activity.
aPosition relative to the translational start site of OPRK1 (NM_000912) on the
NCBI reference genome (NT_008183.18).
bIndividual genomic DNA used as template.
cIndividual 6006 has DNA with the indel; ampliﬁcation using the same primers
produced a fragment with the additional 830 bp indel.
Human Molecular Genetics, 2008, Vol. 17, No. 12 1787DSM-IIIR criteria for alcohol dependence (24) and Feighner
criteria for deﬁnite alcoholism (25); there were 876 affected
and 915 unaffected by this deﬁnition. Because of the possi-
bility of shared genetic vulnerability between dependence on
alcohol and dependence on other illicit drugs, a secondary
analysis was done in which all individuals who were alcohol
dependent were considered affected (876), individuals not
dependent on either alcohol or illicit drugs were considered
unaffected (835), and individuals who were not alcohol depen-
dent but were dependent on illicit drugs were considered
unknown (203). We report results using the PDTaverage
option, which weighs each family equally in computing the
overall test statistic. Linkage disequilibrium between the
indel and SNPs previously genotyped in these families (17)
was evaluated using HAPLOVIEW (32).
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